Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C78H111N23O24 |
| Molecular Weight | 1754.8556 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=CPLZPRMSVOUCIQ-FHSOKALMSA-N
InChI=1S/C78H111N23O24/c1-39(91-70(117)51(14-10-30-86-78(83)84)95-71(118)50(13-8-9-29-79)94-68(115)49(80)23-26-59(81)104)64(111)89-42(4)67(114)99-56(33-45-17-21-48(103)22-18-45)75(122)101-58(35-63(109)110)76(123)96-52(24-27-60(82)105)72(119)100-54(32-44-15-19-47(102)20-16-44)69(116)87-37-61(106)93-57(34-46-36-85-38-88-46)73(120)92-40(2)65(112)90-41(3)66(113)98-55(31-43-11-6-5-7-12-43)74(121)97-53(77(124)125)25-28-62(107)108/h5-7,11-12,15-22,36,38-42,49-58,102-103H,8-10,13-14,23-35,37,79-80H2,1-4H3,(H2,81,104)(H2,82,105)(H,85,88)(H,87,116)(H,89,111)(H,90,112)(H,91,117)(H,92,120)(H,93,106)(H,94,115)(H,95,118)(H,96,123)(H,97,121)(H,98,113)(H,99,114)(H,100,119)(H,101,122)(H,107,108)(H,109,110)(H,124,125)(H4,83,84,86)/t39-,40-,41-,42-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-/m0/s1
| Molecular Formula | C78H111N23O24 |
| Molecular Weight | 1754.8556 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 8 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:53:10 UTC 2023
by
admin
on
Sat Dec 16 11:53:10 UTC 2023
|
| Record UNII |
I99M8K8AXT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
I99M8K8AXT
Created by
admin on Sat Dec 16 11:53:10 UTC 2023 , Edited by admin on Sat Dec 16 11:53:10 UTC 2023
|
PRIMARY | |||
|
16141649
Created by
admin on Sat Dec 16 11:53:10 UTC 2023 , Edited by admin on Sat Dec 16 11:53:10 UTC 2023
|
PRIMARY | |||
|
C104663
Created by
admin on Sat Dec 16 11:53:10 UTC 2023 , Edited by admin on Sat Dec 16 11:53:10 UTC 2023
|
CONCEPT | |||
|
AT-001
Created by
admin on Sat Dec 16 11:53:10 UTC 2023 , Edited by admin on Sat Dec 16 11:53:10 UTC 2023
|
PRIMARY | The purpose of this study is to determine the safety, bioavailability, and effectiveness of an organic yeast-selenium compound in reducing brain oxidative stress. Oxidative stress in the brain has been linked to a variety oif disorders including Alzheimer's disease. Selenium is a very powerful antioxidant that could prove useful in reducing the harmful effects of oxidative stress in the brain and may help prevent diseases such as Alzheimer's. Our recent work has demonstrated that the specific type of selenium compound greatly influences it's ability to enhance brain health and prevent Alzheimer changes in mouse models of this disease. | ||
|
163362-49-0
Created by
admin on Sat Dec 16 11:53:10 UTC 2023 , Edited by admin on Sat Dec 16 11:53:10 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Aratana is pleased to announce positive results from its pivotal field study of AT-001 (Grapiprant), the companys innovative drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p<0.05) at a once-daily oral dose. Aratana expects to commence commercialization upon FDA approval, which Aratana anticipates in 2016.
The blinded, placebo-controlled, multi-center dose-ranging study of AT-001 enrolled 280 client-owned dogs with osteoarthritis. Dogs were randomized equally into one group treated with AT-001 and one group treated with placebo. Dogs were dosed for 28 days, and effectiveness was determined by a standard protocol utilizing a validated owner-assessed pain score.
|
||
|
ACTIVE MOIETY |
AT132-(formerly AT001)
|
